These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24089207)

  • 21. Sphingolactones: selective and irreversible inhibitors of neutral sphingomyelinase.
    Wascholowski V; Giannis A
    Angew Chem Int Ed Engl; 2006 Jan; 45(5):827-30. PubMed ID: 16365835
    [No Abstract]   [Full Text] [Related]  

  • 22. Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase.
    Arenz C; Thutewohl M; Block O; Waldmann H; Altenbach HJ; Giannis A
    Chembiochem; 2001 Feb; 2(2):141-3. PubMed ID: 11828438
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthesis and evaluation of three novel scyphostatin analogues as neutral sphingomyelinase inhibitors.
    Pitsinos EN; Wascholowski V; Karaliota S; Rigou C; Couladouros EA; Giannis A
    Chembiochem; 2003 Nov; 4(11):1223-5. PubMed ID: 14613115
    [No Abstract]   [Full Text] [Related]  

  • 24. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma.
    Mora R; Dokic I; Kees T; Hüber CM; Keitel D; Geibig R; Brügge B; Zentgraf H; Brady NR; Régnier-Vigouroux A
    Glia; 2010 Aug; 58(11):1364-83. PubMed ID: 20607862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sphingolipid metabolizing enzymes as novel therapeutic targets.
    Billich A; Baumruker T
    Subcell Biochem; 2008; 49():487-522. PubMed ID: 18751924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A photocaged inhibitor of acid sphingomyelinase.
    Prause K; Naseri G; Schumacher F; Kappe C; Kleuser B; Arenz C
    Chem Commun (Camb); 2020 Nov; 56(94):14885-14888. PubMed ID: 33179626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological activities of alpha-mangostin derivatives against acidic sphingomyelinase.
    Hamada M; Iikubo K; Ishikawa Y; Ikeda A; Umezawa K; Nishiyama S
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3151-3. PubMed ID: 12951083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sphingolipid metabolism during infection of human fibroblasts by herpes simplex virus type 1.
    Steinhart WL; Busch JS; Oettgen JP; Howland JL
    Intervirology; 1984; 21(2):70-6. PubMed ID: 6321394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of sphingolipid metabolism disruption on lipopolysaccharide-induced lung injury in mice.
    Okuro RT; Machado MN; Casquilho NV; Jardim-Neto A; Roncally-Carvalho A; Atella GC; Zin WA
    Pulm Pharmacol Ther; 2018 Jun; 50():100-110. PubMed ID: 29702255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of fluorescent substrates and their application to study of sphingolipid metabolism in vitro and in intact cells.
    Dagan A; Agmon V; Gatt S; Dinur T
    Methods Enzymol; 2000; 312():293-304. PubMed ID: 11070879
    [No Abstract]   [Full Text] [Related]  

  • 31. Synthesis and evaluation of a difluoromethylene analogue of sphingomyelin as an inhibitor of sphingomyelinase.
    Yokomatsu T; Takechi H; Akiyama T; Shibuya S; Kominato T; Soeda S; Shimeno H
    Bioorg Med Chem Lett; 2001 May; 11(10):1277-80. PubMed ID: 11392536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F-11334s, new inhibitors of membrane-bound neutral sphingomyelinase.
    Tanaka M; Nara F; Yamasato Y; Ono Y; Ogita T
    J Antibiot (Tokyo); 1999 Sep; 52(9):827-30. PubMed ID: 10726931
    [No Abstract]   [Full Text] [Related]  

  • 33. Macquarimicin A inhibits membrane-bound neutral sphingomyelinase from rat brain.
    Tanaka M; Nara F; Yamasato Y; Masuda-Inoue S; Doi-Yoshioka H; Kumakura S; Enokita R; Ogita T
    J Antibiot (Tokyo); 1999 Jul; 52(7):670-3. PubMed ID: 10513848
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice.
    Tabatadze N; Savonenko A; Song H; Bandaru VV; Chu M; Haughey NJ
    J Neurosci Res; 2010 Oct; 88(13):2940-51. PubMed ID: 20629193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sphingolipids in inflammatory hypoxia.
    Glaser UG; Fandrey J
    Biol Chem; 2018 Sep; 399(10):1169-1174. PubMed ID: 29908122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of sphingomyelin sulfur analogue and its behavior toward sphingomyelinase.
    Hakogi T; Fujii S; Morita M; Ikeda K; Katsumura S
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2141-4. PubMed ID: 15808485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of a nitrogen analogue of sphingomyelin as a sphingomyelinase inhibitor.
    Hakogi T; Taichi M; Katsumura S
    Org Lett; 2003 Aug; 5(16):2801-4. PubMed ID: 12889878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An obligate role for membrane-associated neutral sphingomyelinase activity in orienting chemotactic migration of human neutrophils.
    Sitrin RG; Sassanella TM; Petty HR
    Am J Respir Cell Mol Biol; 2011 Feb; 44(2):205-12. PubMed ID: 20378749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereocontrolled synthesis of a sphingomyelin methylene analogue as a sphingomyelinase inhibitor.
    Hakogi T; Monden Y; Iwama S; Katsumura S
    Org Lett; 2000 Aug; 2(17):2627-9. PubMed ID: 10990413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Transcriptional regulation of sphingolipid metabolic enzymes].
    Murate T
    Seikagaku; 2007 Dec; 79(12):1139-43. PubMed ID: 18203454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.